TO COMPARE THE EFFECT OF HYDRALAZINE AND LABETALOL IN LOWERING SEVERE HYPERTENSION IN PREGNANCY
Keywords:
Hydralazine, Labetalol, Mean Arterial Pressure, Pre-EclampsiaAbstract
OBJECTIVE:- To compare the efficacy of intravenous labetalol and intravenous hydralazine in lowering severe hypertension in patients of preeclampsia and pregnancy induced hypertension.
STUDY DESIGN:- Retrospective randomized clinical study
PLACE AND DURATION OF STUDY:- Nishtar hospital, Bakhtawar Amin hospital and CMH hospital Multan from November, 2019 to august, 2020.
METHODOLOGY:- Seventy eight patients admitted in the Obstetrics and Gynaecology department having preeclampsia or severe hypertension fulfilling the inclusion criteria, were enrolled in the study. The detailed data regarding maternal parameters was taken. The readings of systolic, diastolic and mean arterial pressure were taken before and after treatment. The mean fall in mean arterial pressure and time taken from for this was recorded. Data was analysed by using SPSS version 20. RESULTS:- The mean age of patients in hydralazine group(Group A) was 25.4 years while that of labetalol group (Group B) was 25.6 years. The average gestational age of Group A and B patients were 34 and 33 weeks respectively. The mean fall in mean arterial pressure with hydralazine group was 25.31± 4.3 while it was 28.69 ± 4.01with labetalol group with p value <0.001. The time required by Group A and B to achieve the target blood pressure was 25.56 ± 6.7and 22.41 ± 4.23 minutes respectively with p value <0.014. CONCLUSION:- Our study favors the use of intravenous labetalol in preeclampsia and severe hypertension in pregnancy as it lowers mean arterial pressure more as compared to intravenous hydralazine.
KEYWORDS:- Hydralazine, Labetalol, Mean Arterial Pressure, Pre-Eclampsia
References
Wang, W., Xie, X., Yuan, T. et al. Epidemiological trends of maternal hypertensive disorders of pregnancy at the global, regional, and national levels: a population‐based study. BMC Pregnancy Childbirth 21, 364 (2021). https://doi.org/10.1186/s12884-021-03809-2
Braunthal S, Brateanu A. Hypertension in pregnancy: Pathophysiology and treatment. SAGE Open Med. 2019;7:2050312119843700. Published 2019 Apr 10. doi:10.1177/2050312119843700
Ross KM, Dunkel Schetter C, McLemore MR, Chambers BD, Paynter RA, Baer R, et al. Socioeconomic Status, Preeclampsia Risk and Gestational Length in Black and White Women. J Racial Ethn Health Disparities. 2019 Dec;6(6):1182-1191. doi: 10.1007/s40615-019-00619-3. Epub 2019 Jul 31. PMID: 31368002.
Lam MTC, Dierking E. Intensive Care Unit issues in eclampsia and HELLP syndrome. Int J Crit Illn Inj Sci. 2017;7(3):136-141. doi:10.4103/IJCIIS.IJCIIS_33_17
Mark A. Brown, Laura A. Magee, Louise C. Kenny, S. et al. Warren, Gloria Adoyi, Salisu Ishaku; Hypertensive Disorders of Pregnancy. Hypertension. 2018; 72:24-43.
Brown CM, Garovic VD. Drug treatment of hypertension in pregnancy. Drugs. 2014;74(3):283-296. doi:10.1007/s40265-014-0187-7
Katzung BG and Trevor AJ. Basic and clinical pharmacology. 13th ed. New York: McGraw-Hill Education; 2015. 179,181 p.
Khowaja, A.R., Qureshi, R.N., Sheikh, S. et al. Community’s perceptions of pre-eclampsia and eclampsia in Sindh Pakistan: a qualitative study. Reprod Health 2016. 13, 36. https://doi.org/10.1186/s12978-016-0136-x
Gupte S, Wagh G. Preeclampsia-eclampsia. J Obstet Gynaecol India. 2014; 64(1):4-13. doi:10.1007/s13224-014-0502-y
Scantlebury DC, Schwartz GL, Acquah LA, White WM, Moser M, Garovic VD. The treatment of hypertension during pregnancy: when should blood pressure medications be started?. Curr Cardiol Rep. 2013;15(11):412. doi:10.1007/s11886-013-0412-0
Patel P, Koli D, Maitra N, Sheth T, Vaishnav P. Comparison of Efficacy and Safety of Intravenous Labetalol Versus Hydralazine for Management of Severe Hypertension in Pregnancy. J Obstet Gynaecol India. 2018; 68(5):376-381. doi:10.1007/s13224-017-1053-9
Pattraporn Chera-Aree, Pimrapat Tengtrakulcharoen, Jarunee Leetheeragul RN,Urai Sampaojarean RN,Supitchaya Surasereewong, Tuangsit Wataganara. Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women. J. Clin. Pharmacol. 2020; 60(12):1662-1670. https://doi.org/10.1002/jcph.1685
Khan A, Hafeez S and Nasrullah FD. Comparison of Hydralazine and Labetalol to lower severe hypertension in pregnancy. Pak J Med Sci. 2017; 33(2):446-470. Doi: https:/doi.org/10.12669/pjms.332.12243.
Herman LL, Bruss ZS, Tivakaran VS. Hydralazine. [Updated 2021 Jul 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470296/
